CR20210677A - Virus atenuados del dengue - Google Patents
Virus atenuados del dengueInfo
- Publication number
- CR20210677A CR20210677A CR20210677A CR20210677A CR20210677A CR 20210677 A CR20210677 A CR 20210677A CR 20210677 A CR20210677 A CR 20210677A CR 20210677 A CR20210677 A CR 20210677A CR 20210677 A CR20210677 A CR 20210677A
- Authority
- CR
- Costa Rica
- Prior art keywords
- modified
- recoded
- regions
- virus
- combination
- Prior art date
Links
- 241000710829 Dengue virus group Species 0.000 title 1
- 230000002238 attenuated effect Effects 0.000 title 1
- 241000710831 Flavivirus Species 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 108020004705 Codon Proteins 0.000 abstract 1
- 108700010070 Codon Usage Proteins 0.000 abstract 1
- 241000710827 Dengue virus 1 Species 0.000 abstract 1
- 108010067390 Viral Proteins Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962866477P | 2019-06-25 | 2019-06-25 | |
| PCT/US2020/039166 WO2020263850A1 (en) | 2019-06-25 | 2020-06-23 | Attenuated dengue viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210677A true CR20210677A (es) | 2022-04-26 |
Family
ID=74060347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210677A CR20210677A (es) | 2019-06-25 | 2020-06-23 | Virus atenuados del dengue |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220347285A1 (https=) |
| EP (2) | EP3990014A4 (https=) |
| JP (2) | JP2022540773A (https=) |
| CN (1) | CN114302738A (https=) |
| AU (1) | AU2020307532A1 (https=) |
| BR (1) | BR112021026201A8 (https=) |
| CA (1) | CA3145401A1 (https=) |
| CL (1) | CL2021003475A1 (https=) |
| CO (1) | CO2021017772A2 (https=) |
| CR (1) | CR20210677A (https=) |
| DO (1) | DOP2021000271A (https=) |
| IL (1) | IL289274A (https=) |
| MX (1) | MX2022000038A (https=) |
| PE (1) | PE20220296A1 (https=) |
| PH (1) | PH12021553305A1 (https=) |
| WO (1) | WO2020263850A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12178869B2 (en) | 2017-12-22 | 2024-12-31 | Codagenix Inc. | Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer |
| WO2019172982A1 (en) | 2018-03-08 | 2019-09-12 | Codagenix Inc. | Attenuated flaviviruses |
| CN119899808A (zh) * | 2024-12-05 | 2025-04-29 | 深圳湾实验室 | 登革减毒株及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2587084C (en) * | 2004-10-08 | 2019-07-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by using less frequently used synonym ous codons |
| KR101621100B1 (ko) | 2007-03-30 | 2016-05-13 | 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 | 백신에 유용한 약독화 바이러스 |
| US20120269849A1 (en) | 2009-10-09 | 2012-10-25 | Eckard Wimmer | Attenuated influenza viruses and vaccines |
| JP2016523251A (ja) * | 2013-06-21 | 2016-08-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | デングウイルスワクチン組成物およびその使用方法 |
| BR112017004452B1 (pt) * | 2014-09-05 | 2023-12-12 | The Research Foundation For The State University Of New York | Vírus atenuado, arbovírus atenuado, seus usos, composição de vacina, método de produção de um genoma de vírus atenuado, método de produção de um arbovírus atenuado e genoma de arbovírus atenuado |
| US11111481B2 (en) * | 2015-09-30 | 2021-09-07 | Ramot At Tel-Aviv University Ltd. | Attenuated virus mutated at sites of evolutionarily conserved RNA structure |
| CA3016697A1 (en) * | 2016-03-11 | 2017-09-14 | The Johns Hopkins University | Live attenuated zika virus vaccine |
| WO2019172982A1 (en) * | 2018-03-08 | 2019-09-12 | Codagenix Inc. | Attenuated flaviviruses |
-
2020
- 2020-06-23 CA CA3145401A patent/CA3145401A1/en active Pending
- 2020-06-23 CR CR20210677A patent/CR20210677A/es unknown
- 2020-06-23 AU AU2020307532A patent/AU2020307532A1/en active Pending
- 2020-06-23 US US17/621,125 patent/US20220347285A1/en active Pending
- 2020-06-23 MX MX2022000038A patent/MX2022000038A/es unknown
- 2020-06-23 BR BR112021026201A patent/BR112021026201A8/pt unknown
- 2020-06-23 EP EP20833206.4A patent/EP3990014A4/en active Pending
- 2020-06-23 PH PH1/2021/553305A patent/PH12021553305A1/en unknown
- 2020-06-23 CN CN202080060629.9A patent/CN114302738A/zh active Pending
- 2020-06-23 WO PCT/US2020/039166 patent/WO2020263850A1/en not_active Ceased
- 2020-06-23 JP JP2021576889A patent/JP2022540773A/ja active Pending
- 2020-06-23 PE PE2021002239A patent/PE20220296A1/es unknown
- 2020-06-23 EP EP26150104.3A patent/EP4707387A2/en active Pending
-
2021
- 2021-12-22 DO DO2021000271A patent/DOP2021000271A/es unknown
- 2021-12-22 IL IL289274A patent/IL289274A/en unknown
- 2021-12-24 CL CL2021003475A patent/CL2021003475A1/es unknown
- 2021-12-24 CO CONC2021/0017772A patent/CO2021017772A2/es unknown
-
2024
- 2024-12-24 JP JP2024227640A patent/JP2025041836A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021553305A1 (en) | 2022-08-01 |
| CL2021003475A1 (es) | 2023-01-06 |
| IL289274A (en) | 2022-02-01 |
| MX2022000038A (es) | 2022-02-24 |
| WO2020263850A1 (en) | 2020-12-30 |
| EP3990014A1 (en) | 2022-05-04 |
| CA3145401A1 (en) | 2020-12-30 |
| BR112021026201A8 (pt) | 2022-05-10 |
| BR112021026201A2 (pt) | 2022-02-15 |
| CO2021017772A2 (es) | 2022-04-19 |
| CN114302738A (zh) | 2022-04-08 |
| JP2022540773A (ja) | 2022-09-20 |
| US20220347285A1 (en) | 2022-11-03 |
| DOP2021000271A (es) | 2022-04-18 |
| JP2025041836A (ja) | 2025-03-26 |
| AU2020307532A1 (en) | 2022-01-27 |
| PE20220296A1 (es) | 2022-03-07 |
| EP4707387A2 (en) | 2026-03-11 |
| EP3990014A4 (en) | 2023-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551355A1 (en) | Attenuated flaviviruses | |
| CR20210677A (es) | Virus atenuados del dengue | |
| MX2021008146A (es) | Polinucleotidos de arn encapsulado y metodos de uso. | |
| MX2022006365A (es) | Receptores de antigeno quimerico cd19 y cd22 y usos de los mismos. | |
| MX2018007860A (es) | Vacunas recombinantes contra el zika. | |
| MX2019010275A (es) | Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este. | |
| MY192806A (en) | Compositions and methods of vaccination against dengue virus in children and young adults | |
| AR069882A1 (es) | Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e | |
| CU20200037A7 (es) | Derivados de indol-2-carboxamidas sustituidos con amino-tiazol activos contra el virus de la hepatitis b (vhb) | |
| AR118850A1 (es) | Composiciones útiles en el tratamiento de leucodistrofia metacromática | |
| MX374519B (es) | Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas. | |
| CO2018010874A2 (es) | Vacuna de virus de zika atenuado vivo | |
| BR112022001912A2 (pt) | Composições celulares compreendendo vetores virais e métodos de tratamento | |
| UY32721A (es) | Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados | |
| UY32274A (es) | Pestivirus quimericos | |
| MY199422A (en) | Methods of manufacturing an immunogenic composition comprising a recombinant protein | |
| UY32720A (es) | Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados | |
| BR112015021341A2 (pt) | anticorpos neutralizantes de flavivírus e métodos de uso dos mesmos | |
| CO2019010062A2 (es) | Novedoso bacteriófago clo-pep-2 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens | |
| BR112021007105A2 (pt) | Zika vírus recombinante vivo atenuado, zika vírus recombinante, partícula de zika vírus recombinante ou ácido nucleico de zika vírus recombinante, ácido nucleico recombinante, isolado ou substancialmente purificado, vetor, célula ou isolado, vacina, preparação farmacêutica, composição imunogênica, uso, e, métodos para tratar um sujeito com uma infecção viral por zika natural, reduzir a gravidade de uma infecção viral por zika natural em um sujeito ou prevenir um sujeito de contrair uma infecção viral por zika naturalmente, para gerar uma vacina de zika vírus vivo atenuado, zika vírus recombinante, partícula de zika vírus recombinante ou ácido nucleico de zika vírus recombinante e para preparar uma vacina compreendendo zika vírus recombinante vivo atenuado | |
| EA201790778A1 (ru) | Фармацевтические композиции длительного действия от гепатита с | |
| CL2024000481A1 (es) | Proteína de la cápside vp1 modificada aislada de aav9 | |
| TH2001004984A (th) | ฟลาวิไวรัสที่ทำให้ทีมีสภาพอ่อนฤทธิ์ | |
| BR112019008584A2 (pt) | vacinas de mosaico para vírus de doença de pé-e-boca de sorotipo a | |
| MX2022013814A (es) | Tratamiento de infecciones virales. |